Risk Intelligence
Core Model
C+
69 / 100
Fundamentally Qualified
How strong and defensively sound is the company?
Around the middle of the covered universe.
Suggestions
JNJ · NYSE
JOHNSON & JOHNSON
Private betaHealth Care · Pharmaceuticals
$265.58
-0.29%
Close on Sep 11, 2026
Defensively Qualified
Updated 6/30/2026
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
JOHNSON & JOHNSON
Health Care · Pharmaceuticals · Data confidence good
52 / 100
Rank #316 of 1,152 qualified companies
Top 46% · Not Currently Suggested
Long-Term Potential
Research Model
C
62 / 100
Ordinary Compounder
Does the business have the characteristics needed to create value over many years?
Around the middle of the covered universe.
Fundamental Momentum
Research Model
D
43 / 100
Deteriorating
Is the underlying business getting stronger or weaker?
Weaker than most covered companies on this measure.
Ownership Intelligence
Supplemental Intelligence
C−
57 / 100
Positive disclosed activity
What are important owners actually doing?
Around the middle of the covered universe.
Valuation Intelligence
Research Model
F
34 / 100
Expensive
Is today's price reasonable?
Weaker than most covered companies on this measure — and valuation is researched separately from the Suggested Investment Score.
Capital Returns Intelligence
Research Model
C−
60 / 100
Favorable Capital Returns
How effectively does the company reward shareholders?
Around the middle of the covered universe — and capital returns are researched separately from the Suggested Investment Score.
Why it stands out
- Business Quality meets the frozen IA Defensive qualification.
- Price Risk is in the lower-risk category under the frozen IA definition.
- More disclosed holders are new or increasing than reducing or exiting.
What holds it back
- The Fundamental Momentum research model shows deterioration.
- Elevated valuation: the current market price reflects a premium to this company's historical valuation and comparable companies (Valuation Intelligence 34 out of 100, Expensive).
Long-term view
JOHNSON & JOHNSON scores 62 on Long-Term Potential (C), described by the research model as ordinary compounder. This describes business characteristics only — it is not a forecast of future returns.
Ownership view
Disclosed ownership evidence reads 57 (C−): Positive disclosed activity. 21 tracked managers disclosed a position in the latest reporting period. Ownership filings are historical disclosures, not signals.
Valuation view
JOHNSON & JOHNSON reads 34 out of 100 on Valuation Intelligence, recorded as Expensive. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
Capital returns view
JOHNSON & JOHNSON reads 60 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 5.7% a year and a share count falling about 1.8% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What changed
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare JNJ with other companiesResearch Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsAbout a minute to read
The 60-Second Investment Brief
Written from stored research readings only. No hype. No trading signals. Just better evidence.
Why it's interesting
JOHNSON & JOHNSON (JNJ) scores 52 out of 100 and ranks #316 of 1,152 qualified companies today. That places it in the top 46% of ranked companies. The stored tier for that score is not currently suggested.
Business strength
Risk Intelligence reads 69 out of 100 (C+), recorded as fundamentally qualified. Around the middle of the covered universe.
Long-term opportunity
Long-Term Potential reads 62 out of 100 (C), recorded as ordinary compounder. Around the middle of the covered universe.
What's improving or weakening
Fundamental Momentum reads 43 out of 100 (D), recorded as deteriorating. Weaker than most covered companies on this measure.
What important owners are doing
Ownership Intelligence reads 57 out of 100 (C−), recorded as positive disclosed activity. Around the middle of the covered universe.
What kind of price you'd be paying
Valuation is currently the main point of caution: Valuation Intelligence reads 34 out of 100 (F), recorded as Expensive. JOHNSON & JOHNSON reads 34 out of 100 on Valuation Intelligence, recorded as Expensive. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
How the company rewards shareholders
Capital Returns Intelligence reads 60 out of 100 (C−), recorded as Favorable Capital Returns. JOHNSON & JOHNSON reads 60 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 5.7% a year and a share count falling about 1.8% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What could go wrong
The Fundamental Momentum research model shows deterioration. Elevated valuation: the current market price reflects a premium to this company's historical valuation and comparable companies (Valuation Intelligence 34 out of 100, Expensive). Data confidence for this company is good.
Bottom line
No individual layer reaches the strongest band today. Fundamental Momentum and Ownership Intelligence remain the main area to watch. Separately from the score, valuation reads expensive at today's price.
Composite discovery model
Pro Investor Score
Pro Investor Score™
52 / 100
Not Currently Suggested
A 0–100 composite discovery score combining Risk Intelligence, Long-Term Potential, Fundamental Momentum, and Ownership Intelligence. It helps rank qualified companies for further research and does not predict future returns.
- Rank
- #316 of 694
- Percentile
- Top 46%
- Ranking updated
- September 12, 2026
174Rank weakened by 174 positions. Rank weakened by 174 positions.
- Risk Intelligence
- 69
- Long-Term Potential
- 62
- Fundamental Momentum
- 43
- Ownership Intelligence
- 57
30% contribution
30% contribution
20% contribution
20% contribution
Ownership Intelligence
57 / 100 · Moderately Positive · 20% of the Pro Investor Score
SUPPLEMENTAL / DESCRIPTIVE INTELLIGENCE
Coverage: Good
- Elite Investor Activity
- 48 · Mixed
- Institutional Activity
- 80 · Positive
- Insider Activity
- Insufficient Data
- Strategic Ownership
- Insufficient Data
50% of Ownership Intelligence · 10% of the total score
Tracked professional-manager activity is mixed.
20% of Ownership Intelligence · 4% of the total score
Broad institutional evidence from resolved filings is positive.
15% of Ownership Intelligence · 3% of the total score
No discretionary insider transactions are stored for this company, so this evidence is unavailable rather than neutral.
15% of Ownership Intelligence · 3% of the total score
No qualifying major-holder filings are stored, so this evidence is unavailable rather than neutral.
Ownership Intelligence summarizes publicly disclosed activity among professional investment managers, broader institutions, company insiders, and significant strategic owners. It adds context to investment research but is not a validated predictor of future performance. Ownership information is publicly reported with a delay; the latest applicable reporting period is 2026-06-30, publicly disclosed 9/11/2026. Congressional activity is unavailable pending legal review and contributes nothing to this reading.
Why it ranks here
No component ranks in the top quartile of the qualified universe.
What holds it back
Fundamental Momentum is softer
Reported business trends rank below the qualified median.
Ownership evidence is not uniformly supportive
Disclosed elite investor activity evidence is weak or neutral. Ownership evidence is supplemental and never automatically positive.
Ownership evidence disagrees
Different owner groups point in different directions, so the combined reading is best read as mixed rather than uniformly favourable.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Data coverage Excellent. Rankings are recalculated daily using the latest available information. Individual components may update at different frequencies based on when new financial and ownership data becomes available.
Researched separately
Valuation Intelligence 34 · Expensive
RESEARCH MODEL
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 60 · Favorable Capital Returns
RESEARCH MODEL
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Score explanation
Why this company scores the way it does
Four research areas carry fixed weights. Each area is compared against every other eligible company, then weighted. The four contributions below add to 52.0 of the stored score (52.0).
Risk Intelligence
30% of the score · contributes 19.6 points
How strong and defensively sound is the company?
Stands at the 65 percentile of eligible companies · stored reading 69 · 38% of this company’s total score
How financially sturdy the company has been when conditions turned against it.
How this area is measured
Risk Intelligence reads stored balance-sheet strength, historical downside behaviour and the company's price-risk grouping. A stronger reading describes past resilience; it does not protect against future losses.
Full methodologyLong-Term Potential
30% of the score · contributes 21.9 points
Does the business have the characteristics needed to create value over many years?
Stands at the 73 percentile of eligible companies · stored reading 62 · 42% of this company’s total score
Whether the business has the durable characteristics long-term owners look for.
How this area is measured
Long-Term Potential reads durability characteristics such as profitability consistency, cash generation and reinvestment capability over multiple reported periods.
Full methodologyFundamental Momentum
20% of the score · contributes 6.6 points
Is the underlying business getting stronger or weaker?
Stands at the 33 percentile of eligible companies · stored reading 43 · 13% of this company’s total score
Whether the reported business results have been getting stronger or weaker.
How this area is measured
Fundamental Momentum compares recent reported fundamentals with the company's own earlier periods, so improvement or deterioration is measured against its history rather than against a forecast.
Full methodologyOwnership Intelligence
20% of the score · contributes 3.8 points
What are important owners actually doing?
Stands at the 19 percentile of eligible companies · stored reading 57 · 7% of this company’s total score
What large reporting owners have actually been doing with their positions.
How this area is measured
Ownership Intelligence reads public ownership filings: how many tracked reporting owners hold the company, and whether they were adding, holding, reducing or exiting in the latest disclosed period.
Full methodology
What is helping the score
- Long-Term Potential — 73 percentile, adding 21.9 points.
- Risk Intelligence — 65 percentile, adding 19.6 points.
What deserves attention
- Ownership Intelligence — 19 percentile, adding only 3.8 of a possible 20 points.
- Fundamental Momentum — 33 percentile, adding only 6.6 of a possible 20 points.
Outside the score
Additional research — not currently included in the primary Suggested Investment Score.
- Valuation Intelligence — JOHNSON & JOHNSON reads 34 out of 100 on Valuation Intelligence, recorded as Expensive. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
- Capital Returns Intelligence — JOHNSON & JOHNSON reads 60 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 5.7% a year and a share count falling about 1.8% a year.
Pro Investor Intelligence™
Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.
Loading professional-investor activity…
Stored snapshots only
What changed
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence
Is today's price reasonable?
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
34/ 100
Expensive
RESEARCH MODEL
Good coverage
Compared with its history
7
Expensive
Is this company expensive or inexpensive compared with its own history?
Compared with peers
29
Expensive
How expensive is this stock compared with similar companies?
Earnings & cash flow
49
Reasonable
How much financial output does an investor receive relative to the price paid?
Growth-adjusted
60
Reasonable
Does the company's growth help justify the valuation investors are paying?
JOHNSON & JOHNSON reads 34 out of 100 on Valuation Intelligence, recorded as Expensive. The stock currently trades above most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 28, 2026
Valuation history
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current P/E 30.4x · own median 23.7x · peer median 24.4x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence
How effectively does the company reward shareholders?
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
60/ 100
Favorable Capital Returns
RESEARCH MODEL
Excellent coverage
Dividend Quality
80
Strong Capital Returns
Dividend reliability
Buyback Effectiveness
30
Limited Capital Returns
Do buybacks actually reduce shares?
Dilution Control
67
Favorable Capital Returns
Is your ownership share protected?
Capital Return Sustainability
62
Favorable Capital Returns
Can the cash flow support it?
Shareholder Yield
68
Favorable Capital Returns
Cash returned versus company value
JOHNSON & JOHNSON reads 60 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 5.7% a year and a share count falling about 1.8% a year.
How returned cash was used
Dividends $12.62B · net repurchases $3.68B · total returned $16.30B · 73% of free cash flow
Price data through September 11, 2026 · Financial data through the quarter ended June 28, 2026
Capital returns history
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
Why higher yield isn't always better
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Why buybacks can be misleading
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
What these terms mean
- Dividend Yield
- The annual dividend relative to the current share price.
- Payout Ratio
- The share of company earnings used to pay dividends.
- Free Cash Flow Payout
- How much of the company's available cash is being used for dividends.
- Share Repurchases
- When a company buys back its own stock.
- Dilution
- When the number of shares increases, reducing each existing share's percentage ownership of the company.
- Shareholder Yield
- A combined view of dividends and net share repurchases relative to the company's market value.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.
Stored daily snapshots only
Ranking history
| Today | #316 | Score 52 |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | #316 | |
In the company’s own words
What this company does
Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company’s primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887.
The Chief Operating Decision Maker (CODM) is the Company's Chief Executive Officer (Principal Executive Officer). The Executive Committee is Johnson & Johnson’s senior leadership team responsible for setting the strategy and priorities of the Company and driving accountability at all levels. Within the strategic parameters provided by the Executive Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies.
The Company is organized into two business segments: Innovative Medicine and MedTech. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: Item 7. Management’s discussion and analysis of results of operations and financial condition of this Report; and Note 17 Segments of business and geographic areas of the notes to consolidated financial statements included in Item 8 of this Report.
The Innovative Medicine segment is focused on the following therapeutic areas: Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension), Infectious Diseases (e.g., HIV/AIDS) and Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Innovative Medicine segment include: CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; RYBREVANT (amivantamab), a fully-human bispecific antibody for adults with EGFR-mutated non-small cell lung cancer and LAZCLUZE (lazertinib), an oral, brain-penetrant EGFR tyrosine kinase inhibitor for non-small cell lung cancer; RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous therapy for patients with non-small cell lung cancer; TALVEY (talquetamab-tgvs) a bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy; TECVAYLI (teclistamab-cqyv), a bispecific antibody for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy; ZYTIGA (abiraterone acetate), a treatment for patients with prostate cancer; REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active
Quoted from the business section of this company’s 10-K filed February 11, 2026. Read the filing
Four distinct intelligence areas
The IA view
Risk Intelligence
Production core
69
Fundamentally Qualified
+10 vs Jun 30, 2026
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
Long-Term Potential
Research model
63
Elite Compounder
+9.8 vs Jun 30, 2026
Durable business economics and reinvestment characteristics. Independent external validation is pending.
As of Sep 11, 2026
Fundamental Momentum
Research model
43
Middle
+6.9 vs Jun 30, 2026
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
As of Sep 11, 2026
Elite Investor Activity
Supplemental
48
Lower range
0 vs Jun 30, 2026
21 tracked managers disclosed a position for this period.
As of Sep 11, 2026
Company intelligence
JNJ score history
Each area is measured and reported separately. No combined score exists.
JNJ intelligence history from 2023-09-30 to 2026-09-11. Risk Intelligence 68.7 on 2026-09-11, up 10 from 58.7 on 2026-06-30. Long-Term Potential 62.5 on 2026-09-11, up 9.8 from 52.7 on 2026-06-30. Fundamental Momentum 43.1 on 2026-09-11, up 6.9 from 36.2 on 2026-06-30. Elite Investor Activity 47.6 on 2026-09-11, unchanged 0 from 47.6 on 2026-06-30. Each area is reported separately and is never combined into a single score.
Risk Intelligence 68.7 as of Sep 11, 2026 (+10 vs prior period) · Production core
Long-Term Potential 62.5 as of Sep 11, 2026 (+9.8 vs prior period) · Research model
Fundamental Momentum 43.1 as of Sep 11, 2026 (+6.9 vs prior period) · Research model
Elite Investor Activity 47.6 as of Sep 11, 2026 (0 vs prior period) · Supplemental
Share price
JNJ price history
Closing prices adjusted for splits and dividends. Past prices do not indicate future results.
- 6M change
- +10.9%
- 1Y change
- +52.1%
- 3Y change
- +76.4%
- 5Y change
- +84.8%
- Max change
- +118.9%
Last stored close $265.58 · +52.1% over the selected range · 52 sessions shown
Balanced evidence
Why IA likes it
- Business Quality meets the frozen IA Defensive qualification.
- Price Risk is in the lower-risk category under the frozen IA definition.
- More disclosed holders are new or increasing than reducing or exiting.
Risk and uncertainty
What IA doesn’t like
- The Fundamental Momentum research model shows deterioration.
What would change our view
- Business Quality falling below the frozen qualification threshold.
- Price Risk moving to a less favorable category.
- A sustained reversal in the Fundamental Momentum research evidence.
- New material public ownership disclosures.
Public filings · descriptive only
Elite Investor Activity
Reporting holders
79
New holders
52
Increasing
10
Reducing
15
Exiting
0
Coverage
Excellent
Positive disclosed activity · Report period 2023-09-30 · Public 12/27/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
What changed
- Fundamental Momentum
Fundamental Momentum improved
Fundamental Momentum research score moved from 36.2 to 42.9.
- Risk Intelligence
IA Defensive improved
Business Quality qualification score moved from 56.7 to 58.7.
- Fundamental Momentum
Fundamental Momentum softened
Fundamental Momentum research score moved from 65.0 to 36.2.
- Elite Investor Activity
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 38 to 48 for the reporting period ending 2026-06-30.
- Elite Investor Activity
Tracked managers initiated positions
2 tracked managers first disclosed a position for the reporting period ending 2026-03-31.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 53 to 40 for the reporting period ending 2025-06-30.
- Elite Investor Activity
Tracked managers initiated positions
2 tracked managers first disclosed a position for the reporting period ending 2025-03-31.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 94 to 50 for the reporting period ending 2024-12-31.
- Elite Investor Activity
Tracked managers initiated positions
3 tracked managers first disclosed a position for the reporting period ending 2024-12-31.
- Elite Investor Activity
Tracked managers exited positions
3 tracked managers no longer disclosed a position for the reporting period ending 2024-12-31.
Ownership timeline
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.